secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001493152-24-039652
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Biofrontera's sNDA for up to 3 tubes of Ameluz per treatment
-------------------------------------------------------------------------

- FDA increased max dosage from 1 to 3 tubes of Ameluz per PDT treatment for actinic keratosis.
- Approval supported by two Phase 1 safety studies (116 patients) showing equivalent safety profile.
- CEO notes work with Medicare and commercial payers to obtain reimbursement for label update.
- AK affects ~58M people in US; ~13M treatments annually; up to 60% of SCCs start as untreated AK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224039652/0001493152-24-039652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224039652/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-039652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer